Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients.
about
Molecular Targeted Therapies of Aggressive Thyroid CancerTumor-Associated Mast Cells in Thyroid CancerLenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib.High-throughput drug library screening identifies colchicine as a thyroid cancer inhibitorCalvarium and dura mater as delayed sites of distant metastasis from papillary thyroid carcinomaSelective use of vandetanib in the treatment of thyroid cancer.The Chinese herb Prunella vulgaris promotes apoptosis in human well-differentiated thyroid carcinoma cells via the B-cell lymphoma-2/Bcl-2-associated X protein/caspase-3 signaling pathwayLenvatinib: A Review in Refractory Thyroid Cancer.Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.Targeted Therapies in Thyroid Cancer: An Extensive Review of the Literature.Survivin and XIAP - two potential biological targets in follicular thyroid carcinoma.Platelet derived growth factor receptor alpha mediates nodal metastases in papillary thyroid cancer by driving the epithelial-mesenchymal transition.Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial.Sorafenib in the treatment of thyroid cancer.CXCR4/CXCR7/CXCL12-Axis in Follicular Thyroid Carcinoma.Long-term efficacy of lenvatinib for recurrent papillary thyroid carcinoma after multimodal treatment and management of complications: a case report.
P2860
Q26774734-0F6D3B71-847B-45DE-AB33-9671E6D068C3Q26784415-48A7F8EB-80B4-4036-923F-C8A226B6B648Q30243995-F5A55D46-30D1-404A-B880-D09000F2C6C4Q35945841-8C6E4747-A292-4B8E-9D28-A1DAF59B8595Q36208371-23B029DF-4F68-439C-B544-E9D0F9557980Q38546474-53004649-90FE-49F4-9B7D-D455270EBCEEQ38642459-2160CDAE-F914-48C2-875A-50FBC6F4A137Q38729953-56352213-AAAC-4B9C-905D-E7E85C53CB16Q38823954-8CC911C1-E215-4CEF-8F3D-F9999858E1D1Q38883187-D506D4F5-4CBE-4711-A379-379DFC13F4A5Q41200870-A8A4F09F-8D66-415E-B2BF-91523C164BD8Q41968021-345A16EC-1C3E-4B41-95DC-C9D909CDEE0EQ42680724-6FE49416-6698-4941-A751-CFA03C039CEDQ55053748-050A467D-7D9F-4273-A61E-02C7665B76BFQ55229133-5C4C5052-25AA-4054-A096-568EDDCB3398Q55514052-896E389F-F2C9-46D0-91DD-8931F63FF478
P2860
Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Differentiated thyroid cancer: ...... ve iodine-refractory patients.
@ast
Differentiated thyroid cancer: ...... ve iodine-refractory patients.
@en
type
label
Differentiated thyroid cancer: ...... ve iodine-refractory patients.
@ast
Differentiated thyroid cancer: ...... ve iodine-refractory patients.
@en
prefLabel
Differentiated thyroid cancer: ...... ve iodine-refractory patients.
@ast
Differentiated thyroid cancer: ...... ve iodine-refractory patients.
@en
P2860
P1433
P1476
Differentiated thyroid cancer: ...... ve iodine-refractory patients.
@en
P2093
A Dimitrios Colevas
Joshua J Gruber
P2860
P304
P356
10.1634/THEONCOLOGIST.2014-0313
P577
2015-01-23T00:00:00Z